Ranger Investment Management LP Cut Its B&G Foods (BGS) Position; Alere (ALR) Had 2 Analysts Last Week

November 14, 2017 - By Winifred Garcia

Among 7 analysts covering Alere (NYSE:ALR), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Alere had 21 analyst reports since August 4, 2015 according to SRatingsIntel. Canaccord Genuity

maintained the shares of ALR in report on Monday, November 7 with “Buy” rating. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, May 23. Wedbush maintained Alere Inc (NYSE:ALR) rating on Thursday, November 5. Wedbush has “Neutral” rating and $39 target. Canaccord Genuity downgraded the stock to “Hold” rating in Tuesday, February 2 report. The firm has “Outperform” rating given on Thursday, April 28 by Leerink Swann. BTIG Research maintained the stock with “Hold” rating in Thursday, May 25 report. The company was maintained on Thursday, September 29 by Canaccord Genuity. The firm has “Buy” rating by BTIG Research given on Tuesday, August 4. The stock has “Hold” rating by Canaccord Genuity on Tuesday, June 6. The company was downgraded on Tuesday, March 15 by BTIG Research. See Alere Inc (NYSE:ALR) latest ratings:

19/09/2017 Broker: Canaccord Genuity Rating: Hold New Target: $51.0 Maintain
20/07/2017 Broker: Jefferies Rating: Hold New Target: $51.0000 Maintain
06/06/2017 Broker: Canaccord Genuity Old Rating: Buy New Rating: Hold Downgrade
01/06/2017 Broker: Jefferies Rating: Hold New Target: $51.00 Maintain
25/05/2017 Broker: BTIG Research Rating: Hold Maintain
23/05/2017 Broker: Canaccord Genuity Rating: Buy New Target: $51.00 Maintain
15/05/2017 Broker: Craig Hallum Old Rating: Buy New Rating: Hold Downgrade

Ranger Investment Management Lp decreased B&G Foods Inc. (BGS) stake by 84.99% reported in 2017Q2 SEC filing. Ranger Investment Management Lp sold 500,703 shares as B&G Foods Inc. (BGS)’s stock declined 15.06%. The Ranger Investment Management Lp holds 88,441 shares with $3.15 million value, down from 589,144 last quarter. B&G Foods Inc. now has $2.25B valuation. The stock rose 0.75% or $0.25 reaching $33.8. About 232,255 shares traded. B&G Foods, Inc. (NYSE:BGS) has declined 7.13% since November 14, 2016 and is downtrending. It has underperformed by 23.83% the S&P500.

Analysts await B&G Foods, Inc. (NYSE:BGS) to report earnings on February, 22. They expect $0.59 earnings per share, up 103.45% or $0.30 from last year’s $0.29 per share. BGS’s profit will be $39.28M for 14.32 P/E if the $0.59 EPS becomes a reality. After $0.55 actual earnings per share reported by B&G Foods, Inc. for the previous quarter, Wall Street now forecasts 7.27% EPS growth.

Among 12 analysts covering B&G Foods (NYSE:BGS), 5 have Buy rating, 1 Sell and 6 Hold. Therefore 42% are positive. B&G Foods had 36 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Thursday, April 7 by William Blair. The rating was downgraded by Buckingham Research to “Neutral” on Tuesday, May 10. Zacks upgraded the shares of BGS in report on Saturday, August 15 to “Sell” rating. On Monday, October 19 the stock rating was initiated by Buckingham Research with “Neutral”. On Friday, April 21 the stock rating was maintained by RBC Capital Markets with “Buy”. As per Wednesday, October 4, the company rating was maintained by BMO Capital Markets. As per Monday, August 7, the company rating was upgraded by BMO Capital Markets. The rating was upgraded by Zacks to “Sell” on Thursday, August 27. RBC Capital Markets maintained it with “Buy” rating and $5200 target in Tuesday, July 18 report. Buckingham Research maintained B&G Foods, Inc. (NYSE:BGS) on Friday, August 4 with “Neutral” rating.

Ranger Investment Management Lp increased Ross Stores Inc. (NASDAQ:ROST) stake by 5,280 shares to 15,548 valued at $898,000 in 2017Q2. It also upped Maxlinear Inc. (NYSE:MXL) stake by 16,812 shares and now owns 807,150 shares. Calavo Growers Inc. (NASDAQ:CVGW) was raised too.

Alere Inc. is a provider of health information through diagnostic tests. The company has market cap of $4.47 billion. The Company’s divisions include professional diagnostics, consumer diagnostics, and corporate and other. It currently has negative earnings. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.

It closed at $50.99 lastly. It is down 17.58% since November 14, 2016 and is uptrending. It has outperformed by 0.88% the S&P500.


Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: